CompletedNot Applicable

Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

Turkey (Türkiye)60 participantsStarted 2024-03-01

Plain-language summary

This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.

Who can participate

Age range50 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 50-85 years * Clinical Dementia Rating (CDR) score of 1 or2 * Diagnosis of Alzheimer's disease (AD) according to NIA-AA criteria Exclusion Criteria: * Alcohol and/or substance dependence * Diagnosis of chronic renal failure * Diagnosis of another neuropsychiatric disorder * Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol

What they're measuring

Change in Cognitive Function as Measured by the MMSE Score

Timeframe: Baseline and 6 months

Trial details

NCT IDNCT06898424

SponsorProf. Lutfu Hanoglu, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-30

View on ClinicalTrials.gov More Alzheimer Type Dementia trials